lgr4 Antibody

What are the primary applications for LGR4 antibodies in research?

LGR4 antibodies can be utilized in multiple research applications with appropriate validation:

• Western Blot (WB): Detects LGR4 protein (~104.5 kDa) in cell and tissue lysates

• Flow Cytometry (FCM): Identifies LGR4-expressing cell populations

• Immunohistochemistry (IHC): Visualizes LGR4 distribution in tissue sections

• Immunocytochemistry (ICC): Determines subcellular localization in cultured cells

• ELISA: Quantifies LGR4 protein levels in solution

• Neutralization/Blocking: Inhibits LGR4-ligand interactions in functional studies

For optimal results, antibody concentration should be determined empirically for each application. For example, in Western blot applications, a starting concentration of 1-2 μg/ml is recommended, while immunohistochemistry typically requires 10-20 μg/ml .

How can I validate the specificity of an LGR4 antibody?

A comprehensive validation strategy should include:

• Expression system comparison: Test antibody against cells expressing recombinant human or mouse LGR4 versus vector control cells (e.g., HEK293T transfected cells)

• Knockout/knockdown verification: Compare staining between:

  • LGR4 shRNA/siRNA-treated cells vs. control cells

  • LGR4 knockout tissue vs. wild-type tissue

• Cross-reactivity assessment: Test against related family members (LGR5, LGR6) to ensure specificity

• Molecular weight confirmation: Verify correct band size in Western blot (104.5 kDa for full-length human LGR4)

• Cell line panel analysis: Test antibody across cell lines with known LGR4 expression levels (e.g., HT29 positive vs. HCT116 low/negative)

Example validation data from search results showed clone 7E7 specifically detecting human LGR4 while clone 5A3 recognized both human and mouse LGR4, with appropriate molecular weight bands between 110-130 kDa .

What is the optimal fixation protocol for LGR4 immunohistochemistry?

Tissue-specific protocols are essential as fixation requirements vary:

For paraffin-embedded tissues:

• Fix tissue in 10% neutral buffered formalin for 24-48 hours

• Process, embed in paraffin, and section to 4-5 μm thickness

• Deparaffinize sections in xylene

• Rehydrate through graded alcohol series (100%, 95%, 70%, 50%)

• Perform heat-induced antigen retrieval using citrate buffer (pH 6.0) for 20 minutes

• Block with 3-5% normal serum for 1 hour at room temperature

• Incubate with primary LGR4 antibody (10-20 μg/ml) overnight at 4°C

For frozen sections:

• Fix tissues briefly (10 minutes) in 4% paraformaldehyde

• Cryoprotect, freeze, and section (8-10 μm)

• Post-fix sections for 10 minutes in cold acetone

• Block and stain as above, with reduced antibody concentration (5-10 μg/ml)

The specific LGR4 antibody clone and tissue type may require protocol adjustments. For example, clone 5A3 works optimally on mouse tissues while 7E7 is recommended for human tissues .

How do I design experiments to investigate LGR4 function in cancer stem cells?

Cancer stem cell research involving LGR4 requires specialized approaches:

Experimental Design Framework:

• Expression profiling:

  • Use flow cytometry with LGR4 antibodies to isolate LGR4+ cell populations

  • Perform dual staining with established cancer stem cell markers (CD133, ALDH1)

  • Apply single-cell RNA-seq to characterize LGR4+ subpopulations

• Functional assessment:

  • Generate LGR4 knockdown/knockout in cancer cell lines using shRNA or CRISPR-Cas9

  • Assess stemness properties (sphere formation, drug resistance)

  • Measure Wnt pathway activity using reporter assays (TOPFlash)

• In vivo validation:

  • Transplant LGR4+ versus LGR4- cells into immunodeficient mice

  • Utilize LGR4 blocking antibodies in patient-derived xenograft models

  • Monitor tumor initiation capacity and metastatic potential

Research has shown that LGR4 modulates breast cancer initiation, progression, and metastasis in MMTV-PyMT transgenic mice . Additionally, in colorectal cancer, elevated LGR4 expression correlates with chemoresistance through activation of Wnt signaling and regulation of ferroptosis via SLC7A11 upregulation .

What are the critical controls needed when performing LGR4 immunoprecipitation experiments?

Robust immunoprecipitation (IP) experiments for LGR4 require:

Essential Controls:

• Input control: 5-10% of pre-IP lysate to confirm target protein presence

• Isotype control: Matched isotype antibody (e.g., mouse IgG2B for clone 7E7) to assess non-specific binding

• Negative cell line control: Cell line with minimal LGR4 expression (e.g., HCT116)

• IP antibody-only control: Beads plus antibody without lysate

• Knockdown validation: Parallel IP from LGR4 knockdown cells

Optimization Considerations:

• Buffer selection: RIPA buffer for strong interactions; milder NP-40 buffer to preserve weak/transient interactions

• Cross-linking strategy: Use DSP or formaldehyde (0.5-1%) for transient interactions

• Elution method: Compare harsh (SDS, boiling) vs. gentle (peptide competition) elution

• Detection antibody: Use alternative epitope antibody for Western blot detection

When investigating R-spondin/LGR4 interactions, include R-spondin competition controls and test binding using recombinant proteins as demonstrated in R-Spondin 4 binding studies with Lgr4/GPR48-transfected HEK293 cells .

How can discrepancies in LGR4 tissue expression patterns between human and mouse samples be resolved?

Addressing cross-species expression pattern differences requires:

Reconciliation Strategy:

• Multi-antibody approach:

  • Use multiple validated antibodies targeting different epitopes

  • Compare monoclonal (e.g., 7E7, 5A3) vs. polyclonal antibodies

  • Include species-specific antibodies (human-specific 7E7, cross-reactive 5A3)

• Multi-method validation:

  • Correlate protein detection (IHC) with mRNA expression (ISH, qPCR)

  • Compare antibody staining with reporter systems (e.g., LGR4-lacZ mice)

  • Apply RNAscope technology for single-cell resolution

• Standardized protocols:

  • Harmonize tissue processing and staining procedures

  • Use identical antigen retrieval methods across species

  • Implement quantitative scoring systems

Documented Differences:

• In mouse intestine, intense vesicular LGR4 immunoreactivity was observed in Paneth cells and stem cells at the crypt bottom

• In human intestine, only weak diffuse staining was observed in epithelial cells, with stronger staining in stem cells compared to Paneth cells

• In mouse colon, weak cytoplasmic LGR4 staining was found in all cells from crypt bottom to epithelial surface

• In human colon, little to no LGR4 immunoreactivity was observed in epithelial cells

These differences highlight the importance of species-specific controls and multiple detection methods.

What are the optimal conditions for detecting LGR4 by Western blot?

Successful Western blot detection of LGR4 requires specific technical considerations:

Protocol Optimization:

• Sample preparation:

  • Extract proteins using RIPA buffer containing protease inhibitors

  • Include N-ethylmaleimide (5-10 mM) to prevent degradation

  • Heat samples at 70°C (not 95°C) for 10 minutes to prevent aggregation

• Gel selection and transfer:

  • Use 7.5% or 4-12% gradient gels to resolve the ~104.5 kDa protein

  • Transfer to PVDF membrane (not nitrocellulose) at lower voltage (25V) overnight at 4°C

  • Include 10% methanol in transfer buffer for optimal results

• Antibody conditions:

  • Block with 5% non-fat milk in TBST for 2 hours

  • Use primary antibody at 1-2 μg/ml in 5% BSA overnight at 4°C

  • Wash extensively (5×10 minutes) before secondary antibody incubation

• Signal detection:

  • Enhanced chemiluminescence with extended exposure (2-10 minutes)

  • Include both LGR4-positive (HT29) and negative (HCT116) control cell lines

Troubleshooting High Molecular Weight Bands:

• Bands at ~250 kDa likely represent LGR4 dimers/oligomers

• Verify specificity by comparing with vector control cells

• Add reducing agents (DTT, 50-100 mM) to minimize oligomerization

How can I optimize LGR4 detection in flow cytometry experiments?

Flow cytometry optimization for LGR4 requires careful attention to:

Protocol Refinement:

• Cell preparation:

  • Use gentle enzymatic dissociation (e.g., Accutase instead of trypsin)

  • Maintain cells at 4°C throughout staining process

  • Filter cell suspensions through 40 μm mesh before analysis

• Staining procedure:

  • Use 1-5×10⁵ cells per sample in 100 μl staining buffer (PBS + 2% FBS + 0.1% sodium azide)

  • Block Fc receptors with 10% normal serum for 20 minutes

  • Stain with primary antibody (5-10 μg/ml) for 30 minutes on ice

  • For indirect staining, use species-appropriate secondary antibody (e.g., Allophycocyanin-conjugated Anti-Mouse IgG)

• Controls to include:

  • Unstained cells for autofluorescence baseline

  • Isotype control (e.g., Mouse IgG2B) at matching concentration

  • Secondary antibody-only control for indirect staining

  • Positive control (LGR4-transfected cells) and negative control (vector-transfected cells)

• Instrument settings:

  • Optimize voltages using unstained and single-stained controls

  • Collect minimum 10,000 events per sample

  • Use compensation when performing multi-color analysis

This approach has been validated using HEK293 human embryonic kidney cell lines transfected with human LGR4 and eGFP .

What criteria should be used when selecting controls for LGR4 immunohistochemistry in human tissue microarrays?

When analyzing LGR4 expression in tissue microarrays:

Control Selection Guidelines:

• Positive tissue controls:

  • Include sections from tissues with known high LGR4 expression:

    • Skin epidermis (intense staining in basal and granular layers)

    • Reproductive tissues (testis, ovary, uterus)

    • Pancreatic islet cells

    • Kidney tubular epithelium

• Negative tissue controls:

  • Include tissues with minimal reported LGR4 expression:

    • Lung epithelium

    • Hepatocytes

    • Adult brain regions except hippocampus

• Cellular controls:

  • Compare epithelial vs. stromal compartments within each tissue

  • Assess membrane vs. cytoplasmic staining patterns

  • Note vesicular pattern often observed in high-expressing cells

• Technical controls:

  • Include isotype-matched antibody on adjacent sections

  • Use peptide competition (pre-absorb antibody with immunizing peptide)

  • Compare multiple LGR4 antibodies targeting different epitopes

  • Apply multiplicative quick score method for quantification

Additional considerations include assessing whether expression patterns match known pathway activity (e.g., Wnt signaling) in the tissues of interest.

How can LGR4 antibodies be used to investigate LGR4's role in Wnt signaling?

LGR4 antibodies enable several approaches to study Wnt pathway interactions:

Experimental Approaches:

• Co-immunoprecipitation studies:

  • Use LGR4 antibodies to pull down protein complexes

  • Probe for Wnt signaling components (LRP5/6, DVL, β-catenin)

  • Verify R-spondin binding through reciprocal IP

• Blocking experiments:

  • Apply LGR4 antibodies to inhibit R-spondin binding

    • Example: Mouse Anti-Human LGR4 Monoclonal Antibody (MAB7750) blocked binding of biotinylated R-Spondin 4 to HEK293 cells expressing human LGR4

  • Measure downstream Wnt target gene expression (AXIN2, LGR5, etc.)

  • Assess effects on β-catenin nuclear translocation

• Functional assays:

  • Combine LGR4 antibody treatment with Wnt reporter assays (TOPFlash)

  • Monitor stem cell function in organoid cultures

  • Investigate effects on cell survival and proliferation

• Tissue analysis:

  • Correlate LGR4 expression with Wnt target genes in tissue sections

  • Compare normal vs. neoplastic tissues

  • Examine relationship between LGR4 and β-catenin localization

Recent research has demonstrated that blocking LGR4 with monoclonal antibodies can sensitize drug-resistant cancer cells to ferroptosis by inhibiting Wnt-dependent upregulation of SLC7A11 .

What approach should be used to investigate discrepancies between LGR4 antibody staining patterns and mRNA expression data?

Addressing discrepancies requires systematic troubleshooting:

Investigation Strategy:

• Technical validation:

  • Test multiple antibodies targeting different LGR4 epitopes

  • Perform careful titration experiments with each antibody

  • Optimize fixation and antigen retrieval conditions for each tissue type

• Combined detection methods:

  • Perform dual RNA/protein analysis:

    • RNAscope in situ hybridization for mRNA

    • IHC on adjacent sections for protein

  • Follow with laser capture microdissection and qPCR validation

  • Consider single-cell approaches for heterogeneous tissues

• Post-translational regulation assessment:

  • Investigate protein stability (pulse-chase experiments)

  • Examine subcellular localization (fractionation studies)

  • Assess receptor internalization rates (antibody feeding assays)

• Biological variables to consider:

  • Developmental stage (embryonic vs. adult expression)

  • Cell cycle phase (quiescent vs. proliferating cells)

  • Pathological state (normal vs. disease tissue)

The search results revealed that gene reporter assays in transgenic mice showed LGR4 promoter activity in the bottom half of colon crypts, while protein staining showed weak expression throughout colonic epithelium, highlighting potential post-transcriptional regulation .

How can LGR4 antibodies be utilized to investigate endocrine and metabolic disease mechanisms?

LGR4 antibodies offer valuable tools for endocrine/metabolic research:

Research Applications:

• Tissue distribution mapping:

  • Characterize LGR4 expression in:

    • Pancreatic islets

    • Hypothalamic nuclei

    • Gonadal tissues

    • Bone cells

    • Adipose tissue

  • Compare expression patterns in health vs. disease states

• Hormone signaling investigations:

  • Evaluate LGR4 regulation by hormones (testosterone, estrogen, insulin)

  • Assess LGR4 co-localization with hormone receptors

  • Determine effects of LGR4 blockade on hormone production

• Pathological analyses:

  • Compare LGR4 levels in tissues from:

    • Patients with metabolic syndrome vs. healthy controls

    • Individuals with different BMI ranges

    • Subjects with reproductive disorders

  • Correlate LGR4 expression with clinical parameters

• Therapeutic targeting:

  • Develop LGR4-neutralizing antibodies as potential therapeutics

  • Test effects of LGR4 blockade on glucose homeostasis

  • Evaluate impact on bone density and metabolism

Recent studies have implicated LGR4 in several endocrine and metabolic diseases, including hypothalamic-gonadal axis defects, mammary gland dysplasia, osteoporosis, cardiometabolic diseases, and obesity. An inactivating mutation (p.R126X) in LGR4 has been associated with these conditions .

How can LGR4 antibodies be employed to investigate its role in cancer drug resistance mechanisms?

Recent findings suggest LGR4's involvement in chemoresistance:

Experimental Framework:

• Expression analysis in resistant models:

  • Compare LGR4 levels in parental vs. drug-resistant cell lines/organoids

  • Evaluate membrane vs. intracellular LGR4 localization

  • Correlate LGR4 expression with resistance markers

• Functional studies:

  • Generate LGR4 antibody-drug conjugates for targeted therapy

  • Combine LGR4-targeted antibodies with conventional chemotherapeutics

  • Assess effects on cancer stem cell populations and drug efflux

• Mechanistic investigations:

  • Analyze LGR4-dependent signaling in resistant cells:

    • Wnt pathway activity

    • Ferroptosis sensitivity

    • SLC7A11 expression levels

  • Perform RNA-seq after LGR4 antibody treatment

• In vivo validation:

  • Test LGR4 antibodies in patient-derived xenograft models

  • Monitor therapeutic response in organoid cultures

  • Evaluate biomarkers of treatment response

Research has demonstrated that chemoresistant colorectal cancer-derived organoids exhibit elevated LGR4 expression and Wnt signaling activation. Treatment with an LGR4 monoclonal antibody inhibited LGR4-Wnt signaling and sensitized resistant cells to drug-induced ferroptosis by preventing transcriptional upregulation of SLC7A11 .

What considerations are important when designing antibodies for LGR4/R-spondin interaction studies?

For investigating receptor-ligand interactions:

Design Considerations:

• Epitope selection:

  • Target the leucine-rich repeat domains (LRRs) involved in R-spondin binding

  • Avoid the seven-transmembrane domain region for surface-binding antibodies

  • Consider the N-terminal cysteine-rich regions for function-blocking antibodies

• Binding characteristics:

  • Develop antibodies with high affinity (Kd < 10 nM)

  • Select clones that compete with R-spondin binding

  • Consider non-competitive antibodies for detection/localization studies

• Functional properties:

  • Screen for antibodies that:

    • Block R-spondin binding without receptor internalization

    • Induce receptor internalization without signaling

    • Permit R-spondin binding but inhibit downstream signaling

• Validation approaches:

  • Compare multiple R-spondin family members (RSPO1-4)

  • Test in presence of co-receptors (LRP5/6, RNF43/ZNRF3)

  • Assess effects on canonical vs. non-canonical signaling

R&D Systems demonstrated that R-Spondin 4 binding to Lgr4/GPR48-transfected HEK293 cells was completely blocked by Mouse Anti-Human LGR4 Monoclonal Antibody at 2.5 μg/ml, providing a model for functional interaction studies .

How should researchers approach investigating LGR4's potential roles in tissue-resident stem cell regulation?

Stem cell-focused investigations require specialized approaches:

Research Strategy:

• Identification of LGR4+ stem cells:

  • Perform multi-parameter flow cytometry with:

    • LGR4 antibodies

    • Established stem cell markers

    • Functional dyes (side population, ALDH activity)

  • Isolate and characterize LGR4+ populations from different tissues

• Lineage tracing experiments:

  • Use LGR4 antibodies to isolate stem cell populations for transplantation

  • Track differentiation potential in vitro and in vivo

  • Compare with established stem cell markers (LGR5)

• Niche interaction studies:

  • Investigate LGR4 co-localization with niche components

  • Evaluate effects of LGR4 blockade on stem cell-niche interactions

  • Assess consequences on self-renewal vs. differentiation

• Stem cell maintenance assays:

  • Test effects of LGR4 antibodies on:

    • Organoid formation efficiency

    • Long-term culture sustainability

    • Differentiation capacity

  • Examine LGR4 expression during injury repair

Research has shown that LGR4 is highly expressed in epidermal stem cells in the skin, germ cells of the reproductive system, and certain pancreatic islet cells, suggesting important roles in stem cell maintenance in these tissues .

Human Lgr4/GPR48 in HT‑29 Human Cell Line immunofluorescence staining demonstrated specific localization to cell surfaces, indicating potential involvement in stem cell-niche signaling at the membrane level .